
수 종 대사증후군 개선약물이 포볼 에스터 및 상피세포 성장인자로 유발된 기도 MUC5AC 뮤신 유전자 발현 및 생성에 미치는 영향
약물 재창출 전략에 의한 기도점액 과분비 조절약물 탐색
- 이현재(Hyun Jae Lee) 이충재(Choong Jae Lee)
- 대한약학회
- 약학회지
- 제65권 6호
- 등재여부 : KCI등재
- 2021.12
- 424 - 431 (8 pages)
We investigated whether rosiglitazone, metformin, thioctic acid, simvastatin, or glimepiride affects airway MUC5AC mucin gene transcription or protein expression induced by phorbol 12-myristate 13-acetate (PMA) or epidermal growth factor (EGF) in NCI-H292 cells. Cells were pretreated with each agent for 30 min, then stimulated with PMA or EGF for 24 h. Of the five agents, rosiglitazone inhibited PMA-induced gene transcription and production of MUC5AC mucin in NCI-H292 cells. This result suggests that rosiglitazone, an antidiabetic peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist, can inhibit PMA-induced mucin expression at mRNA and protein levels, through directly acting on airway epithelial cells.
서 론(Introduction)
방 법(Methods)
결과 및 고찰(Results and Discussion)
결 론(Conclusion)
References